Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on both a potential treatment for multiple sclerosis (MS) and a dietary supplement for alcohol metabolism. The company’s investigational therapy, Lucid-MS, is designed to target the enzyme PAD2, which is associated with myelin degradation. Unlike conventional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, the protective covering around nerve fibers that is damaged in MS. This approach could offer a novel mechanism to slow or reverse disease progression.
Quantum BioPharma has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial for Lucid-MS. The company is also supporting the development through an imaging collaboration with Massachusetts General Hospital, which may help assess the therapy’s effects on myelin integrity. The progression of Lucid-MS into later-stage trials is a significant milestone, as it could address an unmet need in MS treatment, where current therapies often focus on reducing inflammation but do not directly repair myelin damage.
In parallel, Quantum BioPharma’s proprietary supplement unbuzzd is designed to support alcohol metabolism and reduce acute intoxication and hangover effects. The company cites results from a randomized, placebo-controlled clinical trial that demonstrated the product’s efficacy. unbuzzd has been spun out to Unbuzzd Wellness Inc. (UWI), a company led by industry veterans, with Quantum BioPharma retaining a 19.84% ownership stake (as of March 31, 2026). The agreement also includes royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop pharmaceutical and medical formulations of similar products.
The dual focus on both a disease-modifying therapy for MS and a consumer wellness product for alcohol misuse represents a strategic diversification for the company. While Lucid-MS targets a serious neurological condition with significant medical need, unbuzzd addresses a broader public health issue related to alcohol consumption. The potential revenue from unbuzzd could provide financial support for the more costly clinical development of Lucid-MS. Moreover, the royalty structure ensures long-term income if unbuzzd succeeds commercially.
Quantum BioPharma’s commitment to neurological health is underscored by its pipeline. The company is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative, metabolic, and alcohol misuse disorders. With Lucid-MS advancing toward Phase 2 trials and unbuzzd already on the market, the company is positioning itself at the intersection of pharmaceutical innovation and consumer health. The success of these initiatives could have significant implications for patients with MS and individuals seeking to mitigate the effects of alcohol, potentially improving quality of life and reducing healthcare burdens.
For more information about Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.
To view the full article, visit https://ibn.fm/Rl89U.
